Online Inquiry

RDC Development for Prostate Cancer

As RDC (Radionuclide Drug Conjugate) consists of targeted molecules that act as guides and radionuclides with cell-damaging effects, RDC can be used to treat prostate cancer.

Introduction into Prostate Cancer

Prostate Cancer (PC), the second most common form of cancer in men surpassed only by nonmelanoma skin cancers, is one of the most common cancer types, with an estimated 1.6 million cases and 366 thousand deaths annually. Based on data obtained from 2010 to 2014, the number of new cases of prostate cancer is 119.8 per 100 thousand men per year and the number of deaths was 20.1 per 100 thousand men per year. Even though according to statistical models for analysis, the rates for new prostate cancer cases have been falling for the past 10 years with death rates falling an average of 3.4% each year, attributed to early diagnosis and improved treatment options, the elderly population in the whole world may lead to the prevalence and sheer burden of prostate cancer expects to increase dramatically in the coming decades.

Stages of prostate cancer from I to IV.Fig.1 Stages of prostate cancer from I to IV.

Risk Factors of Prostate Cancer

  • Age, Gene, and Geography
    Prostate cancer ribbon. Age is the most important non-modifiable risk factor of prostate cancer with a rapid increase in age–incidence in the seventh decade. Racial variation of prostate cancer is pronounced. In the USA, compared with European ancestry, African ancestry has 58% greater incidence of prostate cancer and 144% greater mortality, while Hispanic men have 14% lower incidence and 17% lower mortality. Incidence in immigrant populations from developing countries is much lower than the populations in developed countries, which may suggest that genetic factors are more important. Interestingly, the longer length of stay, the lower in incidence, suggesting that lifestyle is another crucial component of prostate cancer risk factor.
  • External Components
    External ionizing and ultraviolet radiation exposure, urinary tract infections, and smoking might play a part in the chronic inflammation and promotion of metastatic spread.

Traditional Therapies for Prostate Cancer

  • Surgery
    Surgical techniques are aimed to remove all cancer tissue and lowering the risk of both complications and side effects.
  • Radiation Therapy
    Newly discovered precise radiation technologies including CRT (Conformal Radiation Therapy), IMRT (Intensity Modulated Radiation Therapy), and proton beam radiation are widely used in prostate cancer treatment, with fewer side effects.
  • HIFU (High-Intensity Focused Ultrasound)
    HIFU is a novel therapeutic strategy for early-stage cancer treatment by heat using highly focused ultrasonic beams.
  • Cryotherapy
    Cryosurgery can damage cancer cells by the destructive force of freezing temperatures on cells.
  • Hormone Therapy
    Hormone therapy works by interfering with many cell pathways, such as blocking the conversion of testosterone to the more active dihydrotestosterone (DHT).
  • Chemotherapy
    Chemotherapy includes cell toxic agents in form of paclitaxel or docetaxel and cabazitaxel interfering with the microtubule system of fast proliferating cancer cells.
  • Immunotherapy
    Immunotherapy can destroy cancer cells through the increased immune system.

Prostate Cancer Treatment with RDC

Targeted Therapy Drugs are the most researched novel therapy recently. RDC (Radionuclide Drug Conjugate), as a newly discovered targeted therapy drug, composed of targeting molecules and radioactive particles, can be applied in prostate cancer treatment.

PSMA (Prostate-Specific Membrane Antigen), overexpressed in metastatic prostate cancer, is a suitable target for imaging and therapy for prostate cancer in clinical. Since PSMA-617 is a PSMA ligand used for prostate cancer therapy, the alpha-emitter 225Ac labeled RDC, 225Ac-PSMA-617, has shown remarkable therapeutic efficacy in heavily pre-treated metastatic castration-resistant prostate cancer patients, as an attractive radioligand therapy option for advanced prostate cancer.

A patient achieved a complete response after three cycles of 225Ac-PSMA617.Fig.2 A patient achieved a complete response after three cycles of 225Ac-PSMA617.
(Sathekge, M., et al., 2019, Eur J Nucl Med Mol Imaging)

Our Service

With top-notched precision platforms and experienced scientists, Rdcthera can offer cost-effective and high-quality RDC-related services, including RDC development and analysis services for worldwide clients. We are honored to share our technology and information with you. Please contact us for more information.


  1. Sathekge, M., Bruchertseifer, F., Knoesen, O., Reyneke, F., Lawal, I., Lengana, T., ... & Morgenstern, A. (2019). 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. European journal of nuclear medicine and molecular imaging, 46(1), 129-138.
For research use only. Not intended for any clinical use.

Rdcthera RDC

Rdcthera offers efficient, customized, and professional R&D services related to radionuclide drug conjugates.

Copyright © Rdcthera. All rights reserved. Privacy Policy | Cookie Policy